JMP Securities Maintains Market Outperform on Protagonist Therapeutics, Raises Price Target to $45
JMP Securities Maintains Market Outperform on Protagonist Therapeutics, Raises Price Target to $45
JMP證券維持Protagonist Therapeutics的市場跑贏大盤,將目標股價上調至45美元
JMP Securities analyst Jonathan Wolleben maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Market Outperform and raises the price target from $42 to $45.
JMP證券分析師喬納森·沃勒本維持Protagonist Therapeutics(納斯達克股票代碼:PTGX)的市場表現跑贏大盤,並將目標股價從42美元上調至45美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。